Key facts
- Oxford Vacmedix’s last known valuation is $53.8M (May 2025).
- It has raised $18.0M; the latest was Later Stage VC ($3.6M) in May 2025.
- Notable investors include Innovate UK, University of Oxford, Cancer Rop Co, Dx & Vx, Oxford University Innovation — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Oxford Vacmedix
- ·The full record, as it builds
Funding rounds
No funding rounds for Oxford Vacmedix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Oxford Vacmedix
Operator of a therapeutic agents development company, intended to deliver immunotherapy for cancer treatment. The company's therapeutic agents are vaccines for cancers and a range of infectious diseases, including tuberculosis, HPV, and Hepatitis B, thus activating the immune system to attack tumors directly, enabling physicians to significantly reduce the need for invasive treatments such as chemotherapy and radiotherapy.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2012
- Employees
- 7
- Website
- oxfordvacmedix.com/
- Ownership
- Privately Held (backing)
Oxford Vacmedix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oxford Vacmedix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oxford Vacmedix in its N-PORT filings yet. We sweep new filings monthly.